In early-February 2020, the first cases of COVID-19 in the United Kingdom (UK) were confirmed. The number of cases in the UK increased significantly at the end of 2021. On January 13, 2023, the number of confirmed cases in the UK amounted to 24,243,393. COVID deaths among highest in Europe There were 202,157 confirmed coronavirus deaths in the UK as of January 13, 2023. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Current infection rate in Europe The current infection rate in the UK was 50 cases per 100,000 population in the last seven days as of January 16. San Marino had the highest seven day rate of infections in Europe at 336.

On March 4, 2020, the first death as a result of coronavirus (COVID-19) was recorded in the United Kingdom (UK). The number of deaths in the UK has increased significantly since then. As of January 13, 2023, the number of confirmed deaths due to coronavirus in the UK amounted to 202,157. On January 21, 2021, 1,370 deaths were recorded, which was the highest total in single day in the UK since the outbreak began.

Number of deaths among highest in Europe
The UK has had the highest number of deaths from coronavirus in western Europe. In terms of rate of coronavirus deaths, the UK has recorded 297.8 deaths per 100,000 population.

Cases in the UK The number of confirmed cases of coronavirus in the UK was 24,243,393 as of January 13, 2023. The South East has the highest number of first-episode confirmed cases of the virus in the UK with 3,123,050 cases, while London and the North West have 2,912,859 and 2,580,090 confirmed cases respectively. As of January 16, the UK has had 50 new cases per 100,000 in the last seven days.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of June 13, 2023, there have been almost 768 million cases of coronavirus (COVID-19) worldwide. The disease has impacted almost every country and territory in the world, with the United States confirming around 16 percent of all global cases.

COVID-19: An unprecedented crisis Health systems around the world were initially overwhelmed by the number of coronavirus cases, and even the richest and most prepared countries struggled. In the most vulnerable countries, millions of people lacked access to critical life-saving supplies, such as test kits, face masks, and respirators. However, several vaccines have been approved for use, and more than 13 billion vaccine doses had already been administered worldwide as of March 2023.

The coronavirus in the United Kingdom Over 202 thousand people have died from COVID-19 in the UK, which is the highest number in Europe. The tireless work of the National Health Service (NHS) has been applauded, but the country’s response to the crisis has drawn criticism. The UK was slow to start widespread testing, and the launch of a COVID-19 contact tracing app was delayed by months. However, the UK’s rapid vaccine rollout has been a success story, and around 53.7 million people had received at least one vaccine dose as of July 13, 2022.

On January 12, 2021, over 4.5 thousand individuals in the UK were admitted to hospital with coronavirus (COVID-19), the highest single amount since the start of the pandemic. The daily hospital cases started to rise significantly at the end of 2020 and into January 2021, however since then the number of hospitalizations fell dramatically as the UK managed to vaccinate millions against COVID-19. Overall, since the pandemic started around 994 thousand people in the UK have been hospitalized with the virus.

The total number of cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Introduction: The first reported UK case of COVID-19 occurred on 30 January 2020. A lockdown from 24 March was partially relaxed on 10 May. One model to forecast disease spread depends on clinical parameters and transmission rates. Output includes the basic reproduction number R0 and the log growth rate r in the exponential phase.Methods: Office for National Statistics data on deaths in England and Wales is used to estimate r. A likelihood for the transmission parameters is defined from a gaussian density for r using the mean and standard error of the estimate. Parameter samples from the Metropolis-Hastings algorithm lead to an estimate and credible interval for R0 and forecasts for cases and deaths.Results: The UK initial log growth rate is r = 0.254 with s.e. 0.004. R0 = 6.94 with 95% CI (6.52, 7.39). In a 12 week lockdown from 24 March with transmission parameters reduced throughout to 5% of their previous values, peaks of around 90,000 severely and 25,000 critically ill patients, and 44,000 cumulative deaths are expected by 16 June. With transmission rising from 5% in mid-April to reach 30%, 50,000 deaths and 475,000 active cases are expected in mid-June. Had such a lockdown begun on 17 March, around 30,000 (28,000, 32,000) fewer cumulative deaths would be expected by 9 June.Discussion: The R0 estimate is compatible with some international estimates but over twice the value quoted by the UK government. An earlier lockdown could have saved many thousands of lives.

The dataset contains a daily situation update on COVID-19, the epidemiological curve and the global geographical distribution (EU/EEA and the UK, worldwide).

On 12 February 2020, the novel coronavirus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while the disease associated with it is now referred to as COVID-19. Since the beginning of the coronavirus pandemic, ECDC’s Epidemic Intelligence team has been collecting on daily basis the number of COVID-19 cases and deaths, based on reports from health authorities worldwide. To insure the accuracy and reliability of the data, this process is being constantly refined. This helps to monitor and interpret the dynamics of the COVID-19 pandemic not only in the European Union (EU), the European Economic Area (EEA), but also worldwide. Every day between 6.00 and 10.00 CET, a team of epidemiologists screens up to 500 relevant sources to collect the latest figures. The data screening is followed by ECDC’s standard epidemic intelligence process for which every single data entry is validated and documented in an ECDC database. An extract of this database, complete with up-to-date figures and data visualisations, is then shared on the ECDC website, ensuring a maximum level of transparency.

ECDC switched to a weekly reporting schedule for the COVID-19 situation worldwide and in the EU/EEA and the UK on 17 December 2020. Hence, all daily updates have been discontinued from 14 December. The weekly data can be found in the dataset COVID-19 Coronavirus data - weekly (from 17 December 2020).

If you reuse or enrich this dataset, please share it with us.

As of October 6, 2022, 11,641 confirmed COVID-19 patients were in hospital in the United Kingdom. The number of COVID patients in hospitals first peaked at over 21.6 thousand on April 12, 2020 and dropped as low as 772 on September 11, 2020. However, the number of patients reached a new peak in the winter of 2020/21 with over 39.2 thousand patients in hospital on January 18, 2021.

The total number of cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

The Coronavirus (COVID-19) Press Briefings Corpus is a work in progress to collect and present in a machine readable text dataset of the daily briefings from around the world by government authorities. During the peak of the pandemic, most countries around the world informed their citizens of the status of the pandemic (usually involving an update on the number of infection cases, number of deaths) and other policy-oriented decisions about dealing with the health crisis, such as advice about what to do to reduce the spread of the epidemic.

Usually daily briefings did not occur on a Sunday.

At the moment the dataset includes:

UK/England: Daily Press Briefings by UK Government between 12 March 2020 - 01 June 2020 (70 briefings in total)

Scotland: Daily Press Briefings by Scottish Government between 3 March 2020 - 01 June 2020 (76 briefings in total)

Wales: Daily Press Briefings by Welsh Government between 23 March 2020 - 01 June 2020 (56 briefings in total)

Northern Ireland: Daily Press Briefings by N. Ireland Assembly between 23 March 2020 - 01 June 2020 (56 briefings in total)

World Health Organisation: Press Briefings occuring usually every 2 days between 22 January 2020 - 01 June 2020 (63 briefings in total)

More countries will be added in due course, and we will be keeping this updated to cover the latest daily briefings available.

The corpus is compiled to allow for further automated political discourse analysis (classification).

Parameter tuning in the UK case.

As of November 24, 2024 there were over 274 million confirmed cases of coronavirus (COVID-19) across the whole of Europe since the first confirmed cases in France in January 2020. France has been the worst affected country in Europe with 39,028,437 confirmed cases, followed by Germany with 38,437,756 cases. Italy and the UK have approximately 26.8 million and 25 million cases respectively. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

COVID-19 rate of death, or the known deaths divided by confirmed cases, was over ten percent in Yemen, the only country that has 1,000 or more cases. This according to a calculation that combines coronavirus stats on both deaths and registered cases for 221 different countries. Note that death rates are not the same as the chance of dying from an infection or the number of deaths based on an at-risk population. By April 26, 2022, the virus had infected over 510.2 million people worldwide, and led to a loss of 6.2 million. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. Note that Statista aims to also provide domestic source material for a more complete picture, and not to just look at one particular source. Examples are these statistics on the confirmed coronavirus cases in Russia or the COVID-19 cases in Italy, both of which are from domestic sources. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

A word on the flaws of numbers like this

People are right to ask whether these numbers are at all representative or not for several reasons. First, countries worldwide decide differently on who gets tested for the virus, meaning that comparing case numbers or death rates could to some extent be misleading. Germany, for example, started testing relatively early once the country’s first case was confirmed in Bavaria in January 2020, whereas Italy tests for the coronavirus postmortem. Second, not all people go to see (or can see, due to testing capacity) a doctor when they have mild symptoms. Countries like Norway and the Netherlands, for example, recommend people with non-severe symptoms to just stay at home. This means not all cases are known all the time, which could significantly alter the death rate as it is presented here. Third and finally, numbers like this change very frequently depending on how the pandemic spreads or the national healthcare capacity. It is therefore recommended to look at other (freely accessible) content that dives more into specifics, such as the coronavirus testing capacity in India or the number of hospital beds in the UK. Only with additional pieces of information can you get the full picture, something that this statistic in its current state simply cannot provide.

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had been confirmed in almost every country in the world. The virus had infected over 687 million people worldwide, and the number of deaths had reached almost 6.87 million. The most severely affected countries include the U.S., India, and Brazil.

COVID-19: background information COVID-19 is a novel coronavirus that had not previously been identified in humans. The first case was detected in the Hubei province of China at the end of December 2019. The virus is highly transmissible and coughing and sneezing are the most common forms of transmission, which is similar to the outbreak of the SARS coronavirus that began in 2002 and was thought to have spread via cough and sneeze droplets expelled into the air by infected persons.

Naming the coronavirus disease Coronaviruses are a group of viruses that can be transmitted between animals and people, causing illnesses that may range from the common cold to more severe respiratory syndromes. In February 2020, the International Committee on Taxonomy of Viruses and the World Health Organization announced official names for both the virus and the disease it causes: SARS-CoV-2 and COVID-19, respectively. The name of the disease is derived from the words corona, virus, and disease, while the number 19 represents the year that it emerged.

Snapshot img

Vaccine Research Market Size 2024-2028

The vaccine research market size is forecast to increase by USD 21.4 billion at a CAGR of 10.84% between 2023 and 2028. The market is witnessing substantial growth due to the persistently high prevalence of infectious diseases and the requirement for innovative vaccines to address chronic infections. Additionally, the advancement of adjuvants and vaccine delivery systems is significantly contributing to market expansion. This growth is driven by the increasing demand for efficient, accessible, and high-standard solutions. Companies in this sector are adapting their strategies to align with these trends, focusing on sustainability and operational efficiency to remain competitive. The market's future direction is influenced by these key drivers, ensuring its continued growth and evolution. As the industry progresses, the demand for advanced solutions continues to expand its scope.

What will be the size of the Vaccine Research Market during the forecast period?

Request Free Vaccine Research Market Sample

Vaccine Research Market Segmentation

The Vaccine Research market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

End-user

  Public
  Private


Age Group

  Pediatric
  Adult


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

Which is the largest segment driving market growth?

The public segment is estimated to witness significant growth during the forecast period.

Government entities, including the US National Institute of Allergy and Infectious Diseases (NIAID) and the US National Institutes of Health (NIH), play a significant role in vaccine research. In response to the COVID-19 pandemic, governments worldwide have made substantial investments in vaccine development, from basic science and pre-clinical stages through clinical trials. These efforts led to the creation of several effective COVID-19 vaccines. Governments have been instrumental in funding and supporting each phase of the vaccine development process. Immunization programs focus on various diseases, such as pneumococcal disease, measles, mumps, mono, and varicella, diphtheria, tetanus, HPV, MMR, rotavirus, influenza, hepatitis, typhoid, meningococcal, rabies, Japanese encephalitis, yellow fever, and polio.

Vaccines come in various forms, including injectable, oral, and nasal, and are produced by vaccine manufacturers, genomic research centers, academic institutions, and private laboratories. They are used in hospital settings, clinics, and pharmacies. Vaccines protect against microorganisms, toxins, and surface proteins, enhancing the immune system's response to pathogens. Vaccine research continues to address physiological disorders, allergies, cancer, and infectious diseases, such as hypertension, dyslipidemia, Alzheimer's, inflammatory diseases, and self-antigens. Vaccines are available as combination vaccines, monovaccines, subunit, recombinant, polysaccharide, live-attenuated vaccines, inactivated vaccines, and DNA vaccines. Vaccines are crucial components of preventive healthcare and public health initiatives, reducing morbidity and mortality.

Get a glance at the market share of various regions. Download the PDF Sample

The Public segment was valued at USD 12.10 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 44% to the growth of the global Vaccine Research market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The market in North America is significantly driven by the high prevalence of both infectious and non-infectious diseases. In the US, influenza, hepatitis A, hepatitis B, HIV, measles, malaria, tuberculosis, and cancer are among the most common health concerns. The prevalence of these diseases continues to increase, particularly in developed countries. For instance, influenza cases peak annually in the US during November to February. Although vaccines have led to a decline in diseases like mumps, measles, and rubella (MMR), they have not been eradicated completely. Vaccine research focuses on various types, including conjugate, recombinant, live attenuated, toxoid, and inactivated vaccines.

These vaccines target various diseases, such as meningitis, pneumonia, and polio. Stakeholders In the market include government immunization programs, preventive healthcare providers, vaccine manufacturers, genomic research centers, academic institutions, private laboratori